论文部分内容阅读
1989年6月起,我们用蝮蛇抗栓酶治疗高凝血症27例,另以27例作对照,治疗期间观察血液流变学变化,现报告如下。对象与方法54例患者经血液流变学指标测定诊断为高凝血症危险期,入院后随机分为抗栓酶组和对照组。抗栓酶组27例,男15例,女12例,年龄53～72岁,平均62.6岁;对照组27例,男14例,女13例,年龄52～72岁,平均66.4岁。54例均有头晕,病程7天～20年,平均6.8年;其中11例肢体麻木,病程7天～9年,平均2.1年。抗栓酶组用蝮蛇抗栓酶每次0.5u 溶于5%GNS300ml 内静滴,每日一次,14天一疗程。少数病人用二个疗程或第二疗程改为每次0.75u 溶于5%GNS300ml 内静滴,每日一次。用
June 1989, we use viper antithrombin enzyme treatment of hypercoagulability in 27 cases, the other 27 cases as a control, observed during the treatment of hemorheological changes, are as follows. Subjects and Methods 54 patients were diagnosed as hypercoagulability risk stage by hemorheology index. After admission, they were randomly divided into antithrombin group and control group. Antithrombin group 27 cases, 15 males and 12 females, aged 53 to 72 years, an average of 62.6 years; control group of 27 patients, 14 males and 13 females, aged 52 to 72 years, mean 66.4 years. 54 cases were dizziness, duration of 7 days to 20 years, an average of 6.8 years; of which 11 cases of limb numbness, duration of 7 days to 9 years, an average of 2.1 years. Antithrombin group with viper antithrombin each 0.5u dissolved in 5% GNS300ml intravenous infusion, once daily, 14 days a course of treatment. A small number of patients with two courses or the second course of treatment to 0.75u each dissolved in 5% GNS300ml intravenous infusion, once daily. use